- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HYPHA LABS Aktie jetzt für 0€ handeln | |||||
| 04.06. | Hypha Labs, Inc.: Hypha Labs Highlights Parallels Between Emerging Psychedelic Industry and Early Cannabis Market Expansion | 220 | ACCESS Newswire | State-Level Reform, Growing Public Acceptance, and Expanding Market Capitalizations Signal Potential Long-Term Industry Opportunity LAS VEGAS, NV / ACCESS Newswire / June 4, 2026 / Hypha Labs, Inc.... ► Artikel lesen | |
| 15.05. | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 27.04. | Hypha Labs, Inc.: Trump Psychedelic Executive Order Accelerates Industry Growth | 333 | ACCESS Newswire | Hypha Labs, Inc. (FUNI) Positioned to Lead with AI-Driven Production Technology LAS VEGAS, NV / ACCESS Newswire / April 27, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology innovator focused on... ► Artikel lesen | |
| 09.04. | Hypha Labs, Inc. Announces Partnership with Mycology Resources, LLC | 408 | ACCESS Newswire | Companies Combine Technology, Cultivation, and Global Distribution LAS VEGAS, NV / ACCESS Newswire / April 9, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology innovator in the functional mushroom... ► Artikel lesen | |
| 30.01. | Hypha Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.01. | Hypha Labs, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 30.12.25 | Hypha Labs, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 01.10.25 | Hypha Labs, Inc.: Hypha Labs and Tryptomics Launch Phase II of Strategic Partnership, Pairing Patented Mushroom Accelerator with World-Class Internal Quality Control & Fungal Genomics | 559 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / October 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, today announced the official... ► Artikel lesen | |
| 29.09.25 | Hypha Labs, Inc.: Hypha Labs and Automated Technical Services Enter into Agreement to Scale its Mushroom Accelerator Technology for Commercial Nutraceutical Manufacturing | 325 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / September 29, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, announced today that it... ► Artikel lesen | |
| 11.08.25 | Hypha Labs, Inc.: Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator | 325 | ACCESS Newswire | Simple, In-Home Eight Day Cycle Generates Significant Yields of The World's Most Popular Mushroom Strains LAS VEGAS, NV / ACCESS Newswire / August 11, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an A.I. powered... ► Artikel lesen | |
| 28.07.25 | Hypha Labs, Inc.: Hypha Labs Provides Shareholder Update | 854 | ACCESS Newswire | LAS VEGAS, NEVADA / ACCESS Newswire / July 28, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 108,12 | 0,00 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| BICARA THERAPEUTICS | 26,870 | 0,00 % | Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC | At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,940 | 0,00 % | Dyne Therapeutics stock initiated at buy by TD Cowen on platform | ||
| IMMIX BIOPHARMA | 9,980 | 0,00 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,130 | 0,00 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 132,62 | +0,05 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 94,81 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,29 | -0,15 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| SAB BIOTHERAPEUTICS | 3,800 | 0,00 % | Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 | ||
| AMYLYX PHARMACEUTICALS | 17,790 | 0,00 % | Amylyx Pharmaceuticals, Inc.: Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 | Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European... ► Artikel lesen | |
| QIAGEN | 34,315 | -0,59 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| TANGO THERAPEUTICS | 31,445 | -0,08 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,720 | 0,00 % | Phathom Pharmaceuticals schließt Rekrutierung für Phase-2-Studie zu EoE ab | ||
| PROKIDNEY | 1,830 | 0,00 % | ProKidney Appoints Kenneth Locke as Chief Technical Officer | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| HUMACYTE | 0,709 | 0,00 % | Humacyte, Inc: Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients | - Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012's primary endpoint and was... ► Artikel lesen |
HYPHA LABS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HYPHA LABS INC finden Sie auf Wallstreet Online.